Emergent BioSolutions (EBS) Return on Capital Employed (2011 - 2026)

Emergent BioSolutions' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 5.18% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 1279.0% year-over-year to 5.18%; the TTM figure through Mar 2026 stood at 5.18% (up 1279.0% YoY), while the FY2025 annual figure was 8.19%, up 1572.0% from the prior year.
• Return on Capital Employed was 5.18% for Q1 2026 at Emergent BioSolutions, down from 7.96% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 9.78% in Q1 2022 to a low of 60.19% in Q4 2023.
• Historically, Return on Capital Employed has averaged 13.66% across 5 years, with a median of 8.55% in 2024.
• The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 6053 bps in 2023, then soared 5164 bps in 2024.
• A 5-year view of Return on Capital Employed shows it stood at 9.43% in 2022, then tumbled by 538 bps to 60.19% in 2023, then jumped by 86 bps to 8.55% in 2024, then jumped by 193 bps to 7.96% in 2025, then slumped by 35 bps to 5.18% in 2026.
• The last three Return on Capital Employed figures came in at 5.18% (Q1 2026), 7.96% (Q4 2025), and 9.1% (Q3 2025), per Business Quant data.